Funder
First Affiliated Hospital, Sun Yat-sen Universtiy
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine
Reference30 articles.
1. National Center for Cardiovascular Diseases C. Report on cardiovascular diseases in China 2017. Beijing: Encyclopedia of China Publishing House; 2017.
2. Hoy SM. Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017;17(2):157–68.
3. Kushiro T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Teramoto T, et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study. Hypertension. 2009;53(2):135–41.
4. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.
5. Ridker PM, MacFadyen JG, Nordestgaard BG, Koenig W, Kastelein JJP, Genest J, et al. Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk: Implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for "Intermediate Risk". Circ: Cardiovasc Qual Outcomes. 2010;3(5):447–52.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献